Re: I'm glad dosing has begun... How long until results...
|
4
|
Resverlogix Corp.
|
Jan 20, 2022 09:52PM
|
Re: I'm glad dosing has begun... How long until results...
|
2
|
Resverlogix Corp.
|
Jan 20, 2022 09:55PM
|
Re: https://scr.zacks.co...
|
4
|
Zenith Epigenetics
|
May 06, 2020 03:21PM
|
Re: https://scr.zacks.co...
|
4
|
Zenith Epigenetics
|
May 05, 2020 07:32PM
|
Re: How many other "Alex Kopacz's" are out there...as we wait our turn on the tarmac?
|
3
|
Resverlogix Corp.
|
Apr 26, 2021 03:36PM
|
Re: How many other "Alex Kopacz's" are out there...as we wait our turn on the tarmac?
|
3
|
Resverlogix Corp.
|
Apr 26, 2021 04:52PM
|
Re: Hope never dies....
|
2
|
Resverlogix Corp.
|
Jun 03, 2021 11:57PM
|
Re: Holy Grail treatment for COVID-19 remains out of reach. But options exist
|
5
|
Resverlogix Corp.
|
Dec 26, 2020 02:46AM
|
Re: Hepa / ORI
|
1
|
Resverlogix Corp.
|
Oct 30, 2020 11:53PM
|
Re: heard back from Sarah..
|
5
|
Resverlogix Corp.
|
Oct 04, 2021 01:20PM
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
4
|
Resverlogix Corp.
|
Apr 12, 2021 07:59PM
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
4
|
Resverlogix Corp.
|
Apr 12, 2021 07:21PM
|
Re: Happy Friday and please send in your votes
|
2
|
Resverlogix Corp.
|
Jun 03, 2022 12:35PM
|
Re: GV on stock house
|
5
|
Resverlogix Corp.
|
Apr 08, 2021 02:53PM
|
Re: GV on stock house
|
4
|
Resverlogix Corp.
|
Apr 08, 2021 03:13PM
|
Re: great,good,bad,ugly or so so??
|
4
|
Resverlogix Corp.
|
May 19, 2022 02:08AM
|
Re: Gonna be a multi billion dollar company soon imo get on board
|
5
|
Resverlogix Corp.
|
Feb 02, 2022 02:05PM
|
Re: Globe - Lessons from accelerated vaccine development - May 25, 2021
|
9
|
Resverlogix Corp.
|
May 26, 2021 06:57PM
|
Re: Gene changes might explain long-haul COVID-19 symptoms .
|
7
|
Resverlogix Corp.
|
Apr 29, 2021 12:55AM
|
Re: From six months ago
|
4
|
Resverlogix Corp.
|
Jun 17, 2021 11:51PM
|